New research reveals that ER+ breast cancer cells acquire aggressive characteristics through direct contact with bone marrow ...

The newly approved methastatic Renal Cell Cancer (mRCC) Phase 1/2a trial began in Q4 2024, and Genenta expects to treat six patients by the end of the first half of 2025, while continuing progress ...

In a personal essay for PEOPLE, TikTok star Eldiara Doucette opens up about her recurring soft tissue cancer, losing her ...

Tumor Infiltrating Lymphocytes (TIL) is under clinical development by Essen Biotech and currently in Phase II for Metastatic Breast Cancer.

Endocrinology specialist Dr Preethi Dissanayake discusses this uncommon presentation, in the latest in our series on ...

The FDA’s breakthrough therapy designation for GSK’227 underscores its potential to address the critical unmet needs of ...

A pioneering study has uncovered the complex and dual roles of neutrophils in cancer development, demonstrating their ...

Onkos Surgical, a leading provider of innovative solutions for complex orthopaedic procedures, today announced that its ...

Recent advancements in medical technology have revolutionized limb-salvage surgery and functional reconstruction for pediatric bone and soft tissue tumors.

Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three-year highs in response to breakthrough innovations and ...